HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

AuthorsJulia K Rotow, Gavitt A Woodard, Anatoly Urisman, Caroline E McCoach, Trever G Bivona, Brett M Elicker, David M Jablons, Collin M Blakely
JournalClinical lung cancer (Clin Lung Cancer) Vol. 20 Issue 2 Pg. e137-e141 (03 2019) ISSN: 1938-0690 [Electronic] United States
PMID30553716 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Crizotinib
  • MET protein, human
  • Proto-Oncogene Proteins c-met
Topics
  • Adenocarcinoma (diagnosis, drug therapy, genetics)
  • Antineoplastic Agents (therapeutic use)
  • Crizotinib (therapeutic use)
  • Exons (genetics)
  • Female
  • Humans
  • Lung Neoplasms (diagnosis, drug therapy, genetics)
  • Middle Aged
  • Mutation (genetics)
  • Neoadjuvant Therapy
  • Prognosis
  • Protein Kinase Inhibitors (therapeutic use)
  • Proto-Oncogene Proteins c-met (genetics)
  • Remission Induction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: